PREVACID 24HR

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

LIBRAX

Gastrointestinal Tract > Hyperacidity, GERD, and ulcers

Chlordiazepoxide HCl 5mg, clidinium bromide 2.5mg; caps.

MAX STR PHAZYME-166

Gastrointestinal Tract > Hyperacidity, GERD, and ulcers

Simethicone 166mg; caps or chew tabs (mint flavor).

MYLANTA MAXIMUM STRENGTH

Gastrointestinal Tract > Hyperacidity, GERD, and ulcers

Aluminum hydroxide 400mg, magnesium hydroxide 400mg, simethicone 40mg; per 5mL; liq; cherry, mint, orange creme, and original flavor.

PREVACID SOLUTAB

Gastrointestinal Tract > Hyperacidity, GERD, and ulcers

Lansoprazole 15mg, 30mg; e-c delayed-release microgranules in orally-disintegrating tabs; strawberry flavor; contains phenylalanine.

ZANTAC SYRUP

Gastrointestinal Tract > Hyperacidity, GERD, and ulcers

Ranitidine (as HCl) 15mg/mL; peppermint flavor; contains alcohol 7.5%.

Gastrointestinal Tract > Hyperacidity, GERD, and ulcers

The management of GERD focuses on the reduction of gastric acidity, increasing lower esophageal sphincter pressure, or enhancing esophageal motility. ...
more »

Important Clinical Information on SAPHRIS^® (asenapine) sublingual tablets

August 25, 2010

Treatment Update for Atrial Fibrillation:
MULTAQ^® (dronedarone) Tablets

July 14, 2010

New Product: MENVEO^® (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine)

June 28, 2010

Xifaxan550 (rifaximin) 550 mg Tablets: Now Approved for Use in Hepatic Encephalopathy

June 03, 2010

Evaluation of Irritable Bowel Syndrome (IBS)

April 09, 2010

Symptom-based criteria such as the Manning Criteria or Rome III Diagnostic Criteria for Irritable Bowel Syndrome (IBS) have been used to enhance the precision of evaluating and diagnosing IBS.

Irritable Bowel Syndrome (IBS) Treatments

March 25, 2010

Drug therapy for the treatment of irritable bowel syndrome (IBS).

H. pylori Eradication Options for Peptic Ulcer Disease

October 08, 2009

Drugs therapies used to treat H. Pylori in peptic ulcer disease (PUD).

Medications with Significant Anticholinergic Properties

October 01, 2009

Commonly prescribed medications that cause significant anticholinergic effect, plus a list of potential adverse consequences.

Gastroesophageal Reflux Disease Management

January 08, 2009